ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer”...
ClearNote Health attended the 14th World CB & CDx Boston Summit. … Virtuoso represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical...
The American Society of Clinical Oncology (ASCO), took place in Chicago, May 31st – June 4th, 2024. We were present at our partner Personalis’ booth #30149. If you missed us, contact us to learn more about how our proprietary, non-invasive 5hmC epigenomic...
We will be at Digestive Disease Week, Washington, DC, May 18th to 21st, 2024. Don’t miss our presentation, titled: “Detection of High-Risk Pancreatic Cysts using Avantect™ blood-based test.”
